Group 1 - The company will hold its 2024 Annual General Meeting on May 20, 2025, combining on-site and online voting methods [2][6] - The meeting will take place at the company's conference room located at No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin [2][10] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the same day, with specific time slots for trading and internet voting [3][4] Group 2 - The agenda includes listening to the independent directors' 2024 annual work report, with no special resolutions or related party voting issues [6][22] - Shareholders must complete voting for all proposals before submission, and multiple accounts can be used for voting, but only the first vote will be counted [8][9][7] - The company will provide a proxy voting option for shareholders unable to attend, with specific documentation required for both individual and corporate shareholders [12][14][20] Group 3 - The company will also hold a 2024 Annual Performance Presentation on May 22, 2025, from 15:00 to 16:30, via the China Securities Journal's website [21][22] - Investors can submit questions via email before the presentation, and the company will address common concerns during the event [21][24] - Key personnel attending the performance presentation include the Vice Chairman, General Manager, and Independent Director [24][25]

证券代码：600645 证券简称：中源协和 公告编号：2025-020 中源协和细胞基因工程股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2025年5月22日15:00-16:30 ●召开地点：中国证券报中证网 （https://www.cs.com.cn/roadshow/yjsmh/） ●召开方式：网络视频播放和网络文字互动 ● 投 资 者 可 在 2025 年 5 月 21 日 17:00 前 通 过 公 司 邮 箱 zhongyuanxiehe@vcanbio.com进行提问，公司将在业绩说明会上对投资者普遍 关注的问题进行回答。或在召开当天15:00-16:30登录中国证券报中证网参与本 次互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2025年4月25 日发布了2024年年度报告。为便于广大投资者更深入全面地了解公司情况，公 司将在中国证券报中证网以网络方式举行2024年度业绩说明会。 二、召开 ...

证券代码：600645 证券简称：中源协和 公告编号：2025-019 中源协和细胞基因工程股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2025年4月25 日在上海证券交易所网站和《中国证券报》、《上海证券报》、《证券时报》刊 登了《关于召开2024年年度股东大会的通知》，定于2025年5月20日以现场投票 和网络投票相结合的方式召开2024年年度股东大会，现将本次股东大会的相关事 项提示如下： 一、 召开会议的基本情况 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 20 日 14 点 00 分 召开地 ...

Core Insights - The article discusses the comprehensive landscape of the stem cell medical industry in China, highlighting the complete industry chain with a mature upstream sector and a developing midstream and downstream sector [1][2]. Industry Chain Overview - The stem cell industry chain consists of three main segments: upstream (stem cell collection and storage), midstream (stem cell proliferation and drug development), and downstream (clinical applications and medical institutions) [1][2]. - Upstream businesses are primarily focused on stem cell collection and storage, ensuring the viability and functionality of stem cells [1]. - Midstream companies engage in technical research and development, including stem cell proliferation and drug development [2]. - Downstream applications involve clinical research and treatment, mainly conducted by top-tier hospitals [1][2]. Regional Distribution - The majority of stem cell medical enterprises are concentrated in Beijing and coastal regions, with significant activity also in Tianjin and Guangdong, and some presence in central regions like Sichuan [5]. Product Sales Performance - Most representative companies in the stem cell medical industry have a product sales rate below 100%, indicating inventory issues [7][8]. - In 2023, companies like Zhongyuan Xiehe and Guanhao Biological reported product sales rates around 100% and 92% respectively, affected by macroeconomic conditions and industry challenges [8]. Mergers and Acquisitions - The industry is experiencing a trend of horizontal integration, focusing on collaboration among similar companies to enhance scale and competitive advantage [9]. - Mergers and acquisitions often involve technology and capital integration, aiming to improve efficacy, reduce costs, and accelerate innovation [9].

截至5月12日收盘，重组蛋白概念下跌0.94%，位居概念板块跌幅榜前列，板块内，迈威生物、泽璟制 药、阿拉丁等跌幅居前，股价上涨的有16只，涨幅居前的有*ST万方、百普赛斯、*ST苏吴等，分别上 涨2.73%、2.69%、2.58%。 今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -3.34 | 3.24 | -9247.96 | | 688266 | 泽璟制药 | -7.80 | 2.14 | -5042.00 | | 300723 | 一品红 | -1.36 | 2.96 | -4614.17 | | 002584 | 西陇科学 | 0.56 | 10.62 | -2062.55 | | 688136 | 科兴制药 | -2.77 | 1.52 | -1992.98 | | 688068 | 热景生物 | -5.39 | 4.08 | -1842.96 | | 600223 | 福瑞达 | -1.08 | 1.40 | -1498.6 ...

Core Points - The company is holding a shareholder meeting on May 20, 2025, to discuss various agenda items including the independent director's report for 2024 and voting on resolutions [1][2] - The company reported a revenue of 1.585 billion yuan for 2024, a slight decrease of 0.27% compared to the previous year, with a net profit of 100 million yuan, down 5.73% [10][11] - The company has made significant progress in stem cell drug development, with multiple clinical trials approved and ongoing for new treatments [12][22] - The company is focusing on enhancing its governance structure and compliance, having received various quality management certifications [17][18] Company Operations - The board of directors has operated in compliance with relevant laws and regulations, approving 32 resolutions with a 100% approval rate [5][6] - The company has established a governance structure involving the shareholder meeting, board of directors, and supervisory board, ensuring clear responsibilities and effective operation [10] - The company has implemented a comprehensive quality management system, achieving ISO certifications in quality, environmental management, and occupational health and safety [17][18] Financial Performance - The company reported a total asset value of 5.249 billion yuan as of December 31, 2024, a decrease of 3% from the previous year [30] - The company’s cash flow from operating activities was negative 64 million yuan, indicating challenges in cash generation [30] - The company has initiated a share buyback program, repurchasing shares worth 200 million yuan, which is 199.32% of its net profit for the year [31] Future Plans - The company aims to deepen its research and development in stem cell therapies and expand its market presence both domestically and internationally [22][24] - The company plans to enhance its automated production capabilities and improve the efficiency of its cell therapy products [23] - The company is committed to building a comprehensive health management ecosystem for families, integrating various health services and insurance collaborations [25]

中源协和细胞基因工程股份有限公司 2024年年度股东大会 会议资料 2025 年 5 月 20 日 中源协和细胞基因工程股份有限公司 2024 年年度股东大会会议议程 现场会议时间：2025 年 5 月 20 日（星期二）14:00。 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开 2、本公司董事、监事及高级管理人员； 3、本公司聘请的股东大会见证律师。 会议议程： 四、审议各项议案，股东提问与解答； | 编号 | | | 议案内容 | | --- | --- | --- | --- | | 1 | 《公司 | 2024 | 年度董事会工作报告》 | | 2 | 《公司 | 2024 | 年度监事会工作报告》 | | 3 | 《公司 | 2024 | 年年度报告》全文及摘要 | | 4 | 《公司 | 2024 | 年度财务决算报告》 | | 5 | 《公司 | 2024 | 年度利润分配预案》 | | 6 | 《公司 | 2025 | 年度 ...

Group 1 - The core viewpoint of the article highlights the competitive landscape of China's stem cell medical industry, focusing on the strengths of Zhongyuan Xiehe and Sailera in their respective fields [1] - Zhongyuan Xiehe specializes in cell therapy for urgent medical care needs, particularly in blood cancers and blood diseases, while Sailera has established a comprehensive industry chain covering research, production, and sales, extending into consumer medical applications [1] - The article provides a comparative analysis of patent applications and values between Sailera and Zhongyuan Xiehe, indicating that Sailera leads in total patent applications while Zhongyuan Xiehe has a higher number of authorized patents [2][5] Group 2 - In terms of patent value, Zhongyuan Xiehe holds a higher proportion of high-value patents, with 40% of its patents valued between 8-10, compared to Sailera's 24% [6] - Sailera has a greater number of collaborative patent applications, including partnerships with foreign companies, while Zhongyuan Xiehe primarily collaborates with domestic entities [10][12] - Both companies focus their patent applications mainly in China, with Sailera having 515 patents filed in China and Zhongyuan Xiehe having 211 [12] Group 3 - Sailera's patent applications are predominantly invention patents, whereas Zhongyuan Xiehe focuses more on utility model patents [14] - The primary technical field for both companies is aligned, but Sailera shows a more pronounced focus in its area of expertise, specifically in the A61K field with 312 applications [16] - Sailera has a higher number of cited patents, indicating a stronger influence in the field, with its most cited patents exceeding 50 citations, compared to Zhongyuan Xiehe's most cited patent with over 40 citations [20] Group 4 - Overall, Zhongyuan Xiehe demonstrates competitive advantages in differentiation and response improvement, while Sailera emphasizes reducing complexity and enhancing speed, showcasing a more comprehensive and diverse technological layout [21]

（一）会计政策变更的原因 重要内容提示： ●本次会计政策变更是公司依据中华人民共和国财政部（以下简称"财政 部"）发布的相关企业会计准则解释而进行的变更，不涉及对公司以前年度的重 大追溯调整，不会对公司的财务状况、经营成果和现金流量产生重大影响，亦不 存在损害公司及股东利益的情况。 一、会计政策变更概述 2024 年 12 月 6 日，财政部发布了《企业会计准则解释第 18 号》（财会〔2024〕 24 号），就"关于浮动收费法下作为基础项目持有的投资性房地产的后续计量"、 "关于不属于单项履约义务的保证类质量保证的会计处理"问题进行规范明确， 该解释自印发之日起施行，允许企业自发布年度提前执行。本公司自该解释印发 之日起施行。 二、会计政策变更的具体情况 证券代码：600645 证券简称：中源协和 公告编号：2025-017 中源协和细胞基因工程股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次公司会计政策变更属于根据国家统一的会计制度要求变更会计政策。 （二）变更前采用的会计政策 本 ...

二、董事会审计委员会年度会议召开情况 报告期，董事会审计委员会共召开了 9 次会议。具体情况如下： 1、2024 年 1 月 29 日，第十一届董事会审计委员会召开了 2024 年第一次会 议暨 2023 年财务审计第一次沟通会。 中源协和细胞基因工程股份有限公司 董事会审计委员会 2024 年度履职情况报告 根据《上市公司治理准则》、《上海证券交易所股票上市规则》、《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》和《公司章程》、《公司董事会 审计委员会工作细则》的有关规定，作为中源协和细胞基因工程股份有限公司（以 下简称"公司"）董事会审计委员会委员，现对 2024 年度履职情况汇报如下： 一、董事会审计委员会基本情况 报告期，公司第十一届董事会审计委员会由独立董事罗明生先生、独立董事 侯欣一先生、董事吴珊女士组成，其中主任委员由具有会计专业资格的独立董事 罗明生先生担任。 会议主要内容为：会计师事务所介绍年报预审情况、审计计划、关键审计事 项等，审计委员会委员、独立董事与会计师、管理层就相关事项进行了沟通。 2、2024 年 4 月 7 日，第十一届董事会审计委员会召开了 2024 年第二次 ...